Therapy of core binding factor acute myeloid leukemia: Incremental improvements toward better long-term results

Vijaya Raj Bhatt, Hagop Kantarjian, Jorge E. Cortes, Farhad Ravandi, Gautam Borthakur

Research output: Contribution to journalArticle

9 Scopus citations


Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number2
Publication statusPublished - Apr 2013
Externally publishedYes



  • Chemotherapy
  • High-dose cytarabine
  • Inversion (16)
  • Response
  • Translocation (8;21)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this